|
|
|
|
PUBLICATIONS
| 2004 |
|
Nov. |
"Drugs
as Materials: Valuing Physical Form in Drug Discovery.",
Colin R. Gardner, Christopher T. Walsh and Örn Almarsson, Nature
Reviews Drug Discovery, Vol 3 No 11. Pages 926-934. November,
2004. |
Sept. |
"Crystal
Engineering of the Composition of Pharmaceutical Phases. Do Pharmaceutical
Co-Crystals Represent a New Path to Improved Medicines?",*
Örn Almarsson and Michael J. Zaworotko, Chemical
Communications, Issue 17, September 7, 2004.
*Amongst the top ten articles accessed on the web from
the online version of Chemical Communications. |
| August |
"Integration
of an Opto-Mechanical Mass Sensor with a Powder-Dispensing Device
for Microgram Sensitivity",
Jeanie Cherng, Javier Gonzalez-Zugasti, Nathan R. Kane, Michael
J. Cima, Anthony V. Lemmo, Journal of the Association of Laboratory
Automation (JALA), Vol. 9, Issue 4. Pages 228-237. August 2004
|
| August |
"A System
for Dispensing Sub-Milligram Doses of Active Pharmaceutical Powders
for Early Stage Solubility Assays",
Nathan R. Kane, Brad Broce, Javier Gonzalez-Zugasti, Wendy
Pryce Lewis, Martin LeQuesne, Anthony V. Lemmo, Journal of the
Association of Laboratory Automation (JALA),Vol. 9, Issue 4. Pages
218-227. August 2004 |
| March |
"High-Throughput
Crystallization: Polymorphs, Salts, Co-crystals and Solvates of Pharmaceutical
Solids," Sherry L. Morissette, Örn Almarsson,
Matthew L. Peterson, Julius F. Remenar, Michael J. Read, Anthony Lemmo,
Steve Ellis, Michael J. Cima and Colin R. Gardner Avd. Drug Del.
Rev., vol. 56(3) pp. 275-300 (2004)
|
| Feb. |
“When
Form Equals Substance: The Value of Form Screening in Product Life-Cycle
Management." John Lucas and Paul Burgess. Pharma
Voice, February, 2004 |
| Feb. |
“The Paxil
Patent: Four Simple Words, One Complex Claim Construction Case."
John Lucas and Paul Burgess. Pharmaceutical Law &
Industry, vol. 2, No. 6, February 6, 2004 |
| Jan. |
“Polymorphism
in Butylated Hydroxy Anisole (BHA)" Jennifer A. McMahon,
Michael J. Zaworotko, and Julius F. Remenar. Chemical Communications,
issue 3, pp. 278-279, (2004) |
| |
“Determination
of P-glycoprotein Inhibition by Excipients and Their Combinations
Using an Integrated High-Throughput Process”, Wang,
S.W., Monagle, J., McNulty, C., Putnam, D., and Chen, H., Journal
of Pharmaceutical Sciences 93 (11), 2755-2767 (2004) |
| |
“Application
of High-Throughput Technologies to Drug Substance and Drug Product
Development”, Gardner, C.R., Almarsson, Ö, Chen,
H., Morissette, S., Peterson, M., Zhang, Z., Wang, S.W., Lemmo, A.,
Gonzalez-Zugasti, J., Monagle, J., Marchionna, J., Ellis, S., McNulty,
C., Johnson, A., Levinson, D., Cima, M. Computers and Chemical
Engineering 28, 943-953 (2004) |
| 2003 |
|
| Nov. |
“Salt Selection
and Simultaneous Polymorphism Assessment via High-Throughput Crystallization:
The Case of Sertraline” Julius F. Remenar, J. Michael
MacPhee, Bridget K. Larson, Viraj A. Tyagi, Jason H. Ho, David McIlroy,
Magali B. Hickey, Paul B. Shaw and Örn Almarsson, Organic
Process Research and Development, November 2003. |
| Nov. |
“High-Throughput
Survey of Crystal Form Diversity of Highly Polymorphic Pharmaceutical
Compounds" Örn Almarsson, Magali B. Hickey, Matthew
L. Peterson, Sherry L. Morissette, Stephen Soukasene, Chris McNulty,
Mark Tawa, J. Michael MacPhee and Julius F. Remenar, Crystal Growth
& Design, November/December 2003, Vol. 3, No. 5. |
| Sept. |
“Crystallization
and Transformation of Acetaminophen Trihydrate” Matthew
L. Peterson, David McIlroy, Paul Shaw, J. Peter Mustonen, Mark Oliveira
and Örn Almarsson, Crystal Growth & Design, September/October
2003, Vol. 3, No. 5, pages 761-765. |
| Aug. |
“A
High-Throughput Combinatorial Approach for the Discovery of a Cremophor
EL-Free Paclitaxel Formulation” Hongming Chen, Zhong
Zhang, Chris McNulty, Cameron Olbert, Hye Jeong Yoon, Jang Won Lee,
Sung Chule Kim, Min Hyo Seo, Hun Seung Oh, Anthony V. Lemmo, Stephen
J. Ellis, and Ken Heimlich, Pharmaceutical Research, August
2003, Vol. 20, No. 8. |
| July |
“Crystal
Engineering of Novel Co-Crystals of a Triazole Drug with 1,4-Dicarboxylic
Acids,” Julius F. Remenar, Sherry L. Morissette, Matthew
L. Peterson, Brian Moulton, J. Michael MacPhee, Héctor Guzmán,
Örn Almarsson, J. Am. Chem. Soc., July 2003, vol. 125,
no. 28, pages 8456-8457. |
| March |
“Elucidation
of Crystal Form Diversity of the HIV Protease Inhibitor Ritonavir
by High-Throughput Crystallization,” Sherry L. Morissette,
Stephen Soukasene, Douglas Levinson, Michael J. Cima, and Orn Almarsson,
PNAS, March 2003, vol. 100, no. 5, pages 2180-2184. |
| Jan. |
“Novel
Approaches to Issues of Developability,” Örn Almarsson,
Colin R. Gardner, Current Drug Discovery, January 2003. |
| 2002 |
|
| Sept. |
“Iterative
High-Throughput Polymorphism Studies on Acetaminophen and an Experimentally
Derived Structure for Form III,” Matthew L. Peterson,
Sherry L. Morissette, Chris McNulty, Andrew Goldsweig, Paul Shaw,
Martin LeQuesne, Julie Monagle, Nicolas Encina, Joseph Marchionna,
Alasdair Johnson, Javier Gonzalez-Zugasti, Anthony V. Lemmo, Stephen
J. Ellis, Michael J. Cima, and Örn Almarsson, J. Am. Chem.
Soc., September 2002, vol. 124, no. 37, pages 10958-10959. |
| Nov. |
“Quinoline
Binding Site on Malaria Pigment Crystal: A Rational Pathway for Antimalaria
Drug Design,” Ronit Buller, Matthew L. Peterson, Örn
Almarsson, and Leslie Leiserowitz, Crystal Growth & Design,
November/December 2002, vol. 2, no. 6, pages 553-562. |
|
|
 |
